Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (291-300 of 539) with videos related to

Pageof 54
Sort By:
International Journal of Cancer|March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myelomaJens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Blood Cancer Journal|August 20, 2024
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significanceHauke Thomsen, Subhayan Chattopadhyay, Niels Weinhold, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
The Lancet. Oncology|September 25, 2010
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trialAnnemiek Broyl, Sophie L Corthals, Joost Lm Jongen, et al.
Plos One|May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletionMarkus Munder, Melanie Engelhardt, Diana Knies, et al.
Pageof 54

Showing results (291-300 of 539) with videos related to

Sort By:
Pageof 54
International Journal of Cancer|March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myelomaJens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Blood Cancer Journal|August 20, 2024
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significanceHauke Thomsen, Subhayan Chattopadhyay, Niels Weinhold, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
The Lancet. Oncology|September 25, 2010
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trialAnnemiek Broyl, Sophie L Corthals, Joost Lm Jongen, et al.
Plos One|May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletionMarkus Munder, Melanie Engelhardt, Diana Knies, et al.
Pageof 54